These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36451866)

  • 1. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
    Luo YD; Liu XY; Fang L; Yu HQ; Zhang YJ; Chen M; Zhang LD; Xie CM
    Theranostics; 2022; 12(18):7903-7919. PubMed ID: 36451866
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
    Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
    Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
    Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
    Makino Y; Hikita H; Kato S; Sugiyama M; Shigekawa M; Sakamoto T; Sasaki Y; Murai K; Sakane S; Kodama T; Sakamori R; Kobayashi S; Eguchi H; Takemura N; Kokudo N; Yokoi H; Mukoyama M; Tatsumi T; Takehara T
    Cell Mol Gastroenterol Hepatol; 2023; 15(1):99-119. PubMed ID: 36210625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
    Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
    Exp Mol Med; 2023 Oct; 55(10):2162-2176. PubMed ID: 37653031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
    J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the molecular interplay and tumorigenesis in hepatocellular carcinoma through insights into FBXL6 and KRAS
    Cai Q; Shubhra QTH
    Mil Med Res; 2024 Feb; 11(1):9. PubMed ID: 38326872
    [No Abstract]   [Full Text] [Related]  

  • 10. A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish.
    Nguyen AT; Emelyanov A; Koh CH; Spitsbergen JM; Lam SH; Mathavan S; Parinov S; Gong Z
    Dis Model Mech; 2011 Nov; 4(6):801-13. PubMed ID: 21729876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
    Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
    Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy.
    Shen Y; Zheng X; Qian Y; Liu M; Nian Z; Cui Q; Zhou Y; Fu B; Sun R; Tian Z; Wei H
    Cancer Sci; 2023 Jun; 114(6):2386-2399. PubMed ID: 36919759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
    Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
    Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
    Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
    Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
    Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
    BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.